Rheumatic diseases are often associated to debilitating chronic pain, which remains difficult to treat and requires new therapeutic strategies. We had previously identified lysophosphatidyl-choline (LPC) in the synovial fluids from few patients, and shown its effect as a positive modulator of Acid-Sensing Ion Channel 3 (ASIC3) able to induce acute cutaneous pain in rodents. However, the possible involvement of LPC in chronic joint pain remained completely unknown. Here we show, from two independent cohorts of patients with painful rheumatic diseases, that the synovial fluid levels of LPC are significantly elevated, especially the LPC16:0 species, compared to post mortem controls. Moreover, LPC16:0 levels are correlated with pain outcomes in a cohort of osteoarthritis (OA) patients. However, LPC16:0 but do not appear to be the hallmark of a particular joint disease, since similar levels are found in the synovial fluids of a second cohort of patients with various rheumatic diseases. The mechanism of action was next explored by developing a pathology-derived rodent model. Intra-articular injections of LPC16:0 is a triggering factor of chronic joint pain in both male and female mice, ultimately leading to persistent pain and anxiety-like behaviors. All these effects are dependent on ASIC3 channels, which drive sufficient peripheral inputs to generate spinal sensitization processes. This study brings evidences from mouse and human supporting a role for LPC16:0 via ASIC3 channels in chronic pain arising from joints, with potential implications for pain management in OA and possibly across other rheumatic diseases.
Several bone conditions e.g., bone cancer, osteoporosis and rheumatoid arthritis (RA) are associated with a risk of developing persistent pain. Increased osteoclast activity is often the hallmark of these bony pathologies and leads not only to bone remodeling but is also a source of pronociceptive factors that sensitize the bone-innervating nociceptors. Although historically bone loss in RA has been thought to be a consequence of inflammation, both bone erosion and pain can occur years before the symptom onset. Here we have addressed the disconnection between inflammation, pain and bone erosion by using a combination of two monoclonal antibodies isolated from B-cells of RA patients. We have found that mice injected with B02/B09 mAbs developed a long-lasting mechanical hypersensitivity which was accompanied by bone erosion in the absence of joint edema or synovitis. Intriguingly, we have noted a lack of analgesic effect of naproxen and a moderate elevation of few inflammatory factors in the ankle joints suggesting that B02/B09-induced pain-like behavior does not depend on inflammatory processes. In contrast, we found that inhibiting osteoclast activity and ASIC3 signaling prevented the development of B02/B09-mediated mechanical hypersensitivity. Moreover, we have identified phospholipase A2 (sPLA2) and lysophospatidylcholine 16:0 as critical components of B02/B09-induced pain-like behavior and shown that treatment with sPLA2 inhibitor reversed B02/B09-induced mechanical hypersensitivity and bone erosion. Taken together, our study suggests a potential link between bone erosion and pain in a state of subclinical inflammation and offers a step forward in understanding the mechanisms of bone pain in diseases like RA.
Exposure to long-chain saturated fatty acids (SFAs; e.g. palmitate) induces apoptosis in pancreatic β cells, a process that may contribute to the development of type 2 diabetes. Under palmitate treatment, β cells undergo a so-called endoplasmic reticulum (ER) stress that can be counteracted by the unfolded protein response (UPR). The UPR is a coordinated response, which is primarily devoted to helping the ER to cope with the accumulation of misfolded proteins. Sustained SFA exposure may ultimately overwhelm the UPR, resulting in cell death. By contrast, unsaturated fatty acids (e.g. oleate) are much less harmful to the cells and can even alleviate palmitate toxicity. Surprisingly, recent evidences indicate that a simple unicellular eukaryote, the budding yeast Saccharomyces cerevisiae, which is not routinely exposed to high-fat diets, also undergoes ER stress under lipotoxic conditions. This suggests that the mechanisms of SFA toxicity are largely conserved throughout eukaryotes and are not specific of a given cell type. The present review discusses the mechanisms of SFA toxicity in yeast and β cells, with a main emphasis on their potential impacts on ER-membrane organization/function and ER-based processes.